In Italia l’Aifa ha autorizzato un vaccino contro l’influenza in spray nasale per i bambini e ragazzi fino ai 18 anni
Risultati per: La composizione del microbioma influenza la depressione
Questo è quello che abbiamo trovato per te
Influenza, 8 i vaccini autorizzati per la stagione 2024-2025
Aifa, ceppi virali aggiornati secondo raccomandazioni dell’Oms
Covid-influenza: rischio stagione «intensa» da 20mila morti, ma il vaccino non piace più
Così dicono i segnali che arrivano dall’emisfero Sud del mondo dove con il passaggio dell’inverno i virus si sono massicciamente affacciati
Sequencing-Based Detection of Avian Influenza A(H5N1) Virus in Wastewater in Ten Cities
New England Journal of Medicine, Ahead of Print.
H5N1 Influenza: What Physicians Need to Know
Annals of Internal Medicine, Ahead of Print.
H5N1 Influenza: What Physicians Need to Know
Annals of Internal Medicine, Ahead of Print.
Verso un'influenza 'intensa', obiettivo i fragili
Vaia, “impegno per la campagna”. In Usa preoccupa l’aviaria
Influenza A(H5N1) Virus Infection in Two Dairy Farm Workers in Michigan
New England Journal of Medicine, Ahead of Print.
Tre porzioni di frutta nella mezza età per prevenire la depressione
Studio, “è una misura contro i sintomi correlati all’invecchiamento”
Il clima influenza gli interventi con il botulino
Il sole incide sull’efficacia.Servono trattamenti personalizzati
Solo 10% degli anziani con vaccino Covid, 50% con anti-influenza
Esperti, organizzazione e comunicazione per aumentare coperture
Communicating the Value of Influenza Vaccines to Patients
Annals of Internal Medicine, Volume 177, Issue 7, Page 990, July 2024.
Communicating the Value of Influenza Vaccines to Patients
Annals of Internal Medicine, Volume 177, Issue 7, Page 990-991, July 2024.
Communicating the Value of Influenza Vaccines to Patients
Annals of Internal Medicine, Volume 177, Issue 7, Page 991, July 2024.
Is Influenza a Risk Factor for Subsequent Acute Myocardial Infarction?
Another study supports an association between influenza and subsequent MI.
INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes
Introduction
Children and adolescents with recent-onset type 1 diabetes (T1D) commonly maintain a certain level of insulin production during the remission phase, which can last months to years. Preserving β-cell function can reduce T1D complications and improve glycaemic control. Influenza vaccination has pleiotropic effects and administration of the vaccine during the early phases of T1D may offer β-cell protection. This study aims to assess the effect of influenza vaccination on preserving β-cell function in children and adolescents with recent-onset T1D.
Methods and analysis
The INfluenza VaccInation To mitigate typE 1 Diabetes trial is a randomised, double-blind, placebo-controlled, multicentre trial in paediatric patients with recent-onset T1D aged 7–17 years. 100 participants will be randomised in a 1:1 ratio to receive either a standard inactivated quadrivalent influenza vaccine or a placebo within 14 days of diagnosis. The primary outcome is a difference in mean change (from baseline to 12 months) in C-peptide level between groups during a 2-hour mixed-meal tolerance test. Secondary outcomes include mean change (from baseline to 6 months) in C-peptide levels, haemoglobin A1c, ambulatory glucose profiles and insulin requirements. Exploratory outcomes are diabetes-related autoantibodies, inflammatory markers and serum haemagglutinin inhibition antibody titres against the influenza viruses. The current treatment for T1D is largely symptomatic, relying on insulin administration. There is a pressing need for novel pharmacological approaches aimed at modulating the immune system to preserve residual β-cell function. Existing immunotherapies are cost-prohibitive and associated with multiple side effects, whereas influenza vaccination is inexpensive and generally well tolerated. A positive outcome of this study holds potential for immediate implementation into standard care for children and adolescents with recent-onset T1D and may guide future research on immune modulation in T1D.
Ethics and dissemination
Ethical approval was obtained from Danish Health Authorities prior to participant enrollment. The trial results will be submitted to a peer-reviewed journal.
Trial registration number
ClinicalTrials.gov NCT05585983 and EudraCT Number 2022-500906-17-01.